[
  {
    "newsArray": [
      { "siteName": "医药魔方" },
      { "siteName": "财联社" },
      { "siteName": "格隆汇" }
    ],
    "summary": "百济神州在研BCL2抑制剂索托克拉治疗套细胞淋巴瘤的1/2期临床研究取得积极结果，公司计划公布数据并推动该药物在美欧等地的审批。",
    "id": "8mDZgjlDotK",
    "order": 1756484737250,
    "createdAt": "2025-08-29T16:25:45.000Z",
    "publishDate": "2025-08-29T16:25:37.250Z",
    "title": "百济神州：索托克拉临床试验取得积极结果",
    "type": "topic",
    "up": false,
    "date": "2025-08-30 00:25:45",
    "uuid": "b697c472-e2a2-4c32-ba83-971f683f2060"
  },
  {
    "newsArray": [
      { "siteName": "格隆汇" },
      { "siteName": "财联社" },
      { "siteName": "华尔街见闻" }
    ],
    "summary": "城堡证券二季度净交易收入为23.9亿美元，较去年同期下滑8.4%。上半年净交易收入达57.8亿美元，净利润为26.6亿美元，同比增长20% ...",
    "id": "8mDyxnSwbuB",
    "order": 1756484737801,
    "createdAt": "2025-08-29T16:25:43.000Z",
    "publishDate": "2025-08-29T16:25:37.801Z",
    "title": "城堡证券二季度交易收入降幅超过8%，净利润锐减超20%",
    "type": "topic",
    "up": false,
    "date": "2025-08-30 00:25:43",
    "uuid": "ce6bb3c3-651c-4ca6-aa0c-9c37791eda8c"
  },
  {
    "newsArray": [
      { "siteName": "界面" },
      { "siteName": "第一财经" },
      { "siteName": "财联社" }
    ],
    "summary": "中央汇金上半年增持多只ETF产品，包括科创板50ETF、沪深300ETF、中证500ETF、中证1000ETF等，涵盖多家基金公司旗下产品。",
    "id": "8mDy2FO00Uu",
    "order": 1756483359017,
    "createdAt": "2025-08-29T16:02:44.000Z",
    "publishDate": "2025-08-29T16:02:39.017Z",
    "title": "中央汇金上半年增持科创板50ETF等10余只ETF产品",
    "type": "topic",
    "up": false,
    "date": "2025-08-30 00:02:44",
    "uuid": "ab8a4f40-728f-4750-b998-5ce7f236d56e"
  }
]
